What's hot
What's hot
News flashes are posted here frequently to keep you up-to-date with the latest advances in health and longevity. We have an unparalleled track record of breaking stories about life extension advances.
- D for depression
- Fisetin combined with aerobic training boosts pro-resolving mediator, lowers inflammation
D for depression
June 03 2026. A dose-response meta-analysis of clinical trials found an association between the addition of vitamin D to the diet and improvement in depressive symptoms. The results were reported March 16, 2026, in Frontiers in Nutrition.
June 03 2026. A dose-response meta-analysis of clinical trials found an association between the addition of vitamin D to the diet and improvement in depressive symptoms. The results were reported March 16, 2026, in The meta-analysis included 15 randomized, controlled trials that examined the effects of vitamin D on depression severity and other factors among a total of 962 men and women diagnosed with depressive disorders. Treatment groups received oral, parenteral, intravenous or intramuscular forms of the vitamin. Trial duration ranged from eight weeks to ten months.
The meta-analysis found significant improvement in depressive symptoms among individuals who received vitamin D compared with the control groups. Additionally, serum parathyroid hormone (PTH) and tumor necrosis factor-alpha (TNF-a) were lower in people who received vitamin D. Dose-response analysis of the trial findings revealed that higher daily vitamin D doses of up to 5,000 international units (IU) per day were associated with the greatest decrease in symptoms of depression.
"In this study, we aimed to consolidate all data from RCTs involving patients diagnosed with depression who received vitamin D," authors Hsuan-Hsien Li of Linkou Chang Gung Memorial Hospital in Taiwan and associates wrote. "The observed reductions in serum PTH and TNFα levels suggest anti-inflammatory mechanisms underlying its antidepressant effects."
"This is the first meta-analysis employing dose–response analysis to evaluate the effect of vitamin D on depression," they announced. "Higher daily intakes, particularly around 5,000 IU, were associated with greater symptom improvement; however, further high-quality trials are required to confirm optimal dosing and long-term safety."
—D Dye
Fisetin combined with aerobic training boosts pro-resolving mediator, lowers inflammation
June 01 2026. A randomized, controlled trial reported in 2026 in the Journal of the International Society of Sports Nutrition resulted in reduced inflammation and an increase in the specialized pro-resolving mediator maresin-1 in obese men assigned to interval resistance-aerobic training plus 200 daily fisetin.
June 01 2026. A randomized, controlled trial reported in 2026 in the "Fisetin, a naturally occurring flavonoid, possesses antioxidant, anti‑inflammatory, and senolytic properties," Mehran Alipour and colleagues wrote. "In cellular and animal models, fisetin has been shown to inhibit inflammatory signaling pathways (including NF‑κB), reduce oxidative stress, and shift macrophage polarization toward reparative phenotypes; there is also preliminary evidence that fisetin may support the production or preservation of specialized pro-resolving mediators."
Pro-resolving mediators such as maresin-1 are made in the body from omega-3 fatty acids to promote a healthy post-inflammatory response.
The trial included 11 men who were given 200 mg fisetin per day without interval resistance-aerobic training, 11 assigned to interval training and a placebo, 11 assigned to 200 mg fisetin per day plus interval training and 11 who received a placebo and no training. Blood levels of maresin-1 and markers of inflammation and metabolism were measured at the beginning and end of the trial.
After 12 weeks, men who received fisetin alone had reductions in the inflammatory markers interleukin-6 and tumor necrosis factor-alpha, as well as metabolic factors that included fasting blood glucose, insulin and insulin resistance. Men who were assigned to training with or without fisetin showed significant increases in maresin-1 in addition to the same improvements observed in the group that received fisetin without training. The greatest increase in maresin-1 and reductions in metabolic markers in comparison with the beginning of the trial occurred among men who were assigned to training plus fisetin. "The synergy between exercise‑induced adaptations and fisetin's anti‑inflammatory properties offers a promising nonpharmacological strategy for mitigating obesity‑related metabolic risk," the authors concluded.
—D Dye
